Why PLL Therapeutics chose Australia to launch its phase I/II clinical trial
Read our article in Clinical Leader on ‘Long-distance rare disease trials: Why PLL landed on Australia and New Zealand’:...
30 September, 2026
News & Resources
PLL THERAPEUTICS
How the gut-brain axis is reshaping our understanding of ALS
An exclusive interview in International Clinical Trials © Samedan Ltd with our CEO Jean Pascal Zambaux provides insights on the growing evidence of linking the gut-brain axis to Amyotrophic Lateral Sclerosis (ALS) and how microbiome profiling and gut-derived biomarkers are promising avenues for earlier detection of ALS. The article looks closely at the role of dysbiosis in neurodegeneration, while highlighting the emerging research revealing new approaches to diagnosis and treatment....
30 September, 2026
Exclusive interview in Pharmaceutiques with Jean Pascal Zambaux
Exclusive interview in Pharmaceutiques with Jean Pascal Zambaux, CEO, who explains how PLL Therapeutics is revolutionizing ALS care with an early-stage blood test (92% sensitivity) to detect the disease before symptoms appear, and a therapy targeting dysbiosis via the gut-brain axis. The challenge: to intervene before 70% of motor neurons are destroyed....
14 May, 2026
PLL Therapeutics reports positive safety and tolerability results from phase I/II trial in ALS (Amyotrophic Lateral Sclerosis)
Stage one results from PLL Therapeutics’ first-in-human, multi-stage phase I/II trial show favorable safety and tolerability of PLL001 in 12 ALS patients. Australian multi-stage study tested single ascending subcutaneous doses of PLL001 – in three dose cohorts - with placebo control....
18 February, 2026
PLL Therapeutics opens subsidiary in New Zealand to accelerate ALS (Amyotrophic Lateral Sclerosis) treatment and early diagnostics breakthroughs
Expansion in Asia-Pacific with second subsidiary, following Australia, pivotal to enrolling patients in phase II trial targeting ALS, a motor neuron disease with no cure....
10 December, 2025
PLL Therapeutics presents strategic approach for early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at Bioshares Biotech Summit
Talk will highlight for investors role of PLL Therapeutics’ poly-L-Lysine-based therapy in helping combat neurodegenerative disorders and in early-stage and companion biomarkers....
06 August, 2025
PLL Therapeutics welcomes Dr. Philippe Corcia, leading genetics and rare disease specialist, to scientific board
Preeminent researcher in Amyotropic Lateral Sclerosis (ALS), Dr. Corcia heightens expertise behind PLL Therapeutics’ polypeptide delivery platform and development of world’s first blood biomarker to detect early onset of ALS...
24 June, 2025
PLL Therapeutics enrolls first patient in phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS)
Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo...
15 April, 2025
PLL Therapeutics obtains authorization to start phase I/II trial in Australia for patients with Amyotrophic Lateral Sclerosis (ALS)
Australia’s Human Research Ethics Committees (HREC) cleared first-in-human study of drug candidate PLL001. PLL001 aims at restoring microbiome and stopping gut from leaking to treat root cause of ALS, not solely symptoms...
19 November, 2024
And the winner is …
The intestine is well known to be our second brain and nearly 500 million neurons line our intestine (20 times less than our brain). But in the history of humanity was not the intestine our first Brain? The first primitive organisms were a simple digestive tract!...
25 March, 2024
Resources
PLL THERAPEUTICS : DRIVING A NEW APPROACH TO ALS DIAGNOSIS AND THERAPY
PLL Therapeutics is developing a new paradigm for the early diagnosis and treatment of patients with amyotrophic lateral sclerosis. Our pioneering therapy, currently undergoing a Phase I/II study, is based on emerging insights into the role of the gut-brain axis in the pathophysiology of the condition, while our investigational diagnostic identifies patients on the basis of a unique serum antibody signature.
